A promising RSV drug could soon be offered for toddlers : NPR

According to recent reports by NPR, a promising drug to treat Respiratory Syncytial Virus (RSV), a virus that is especially dangerous for small children, could soon be available for toddlers.

The reported drug is an inhalable powder that was approved by the Food and Drug Administration (FDA) in February of 2018. It is a single-dose powder that can be inhaled at home, and it has already been shown to be effective in reducing the spread of the virus in young infants.

The drug, known as Synagis, is made of antibodies that help fight off RSV and is the only FDA-approved drug that can be used in children. Because the virus is so contagious, it is especially important that the drug be available to toddlers and young children who are most vulnerable to its spread.

What makes this drug unique is that it is the first to be approved for children this young, as well as the first to be taken at home, giving parents a much-needed solution for keeping their children safe from this virus.

The drug will cost about $3,500 for a full year’s supply, and is likely to be available sometime in the next few months. This news is particularly exciting for parents and medical professionals, as it will be one of the few treatments available for the prevention of RSV.

The potential of this drug is very promising, and it could potentially be invaluable in stopping the spread of RSV among young children. With the current level of virus activity, the availability of this drug could greatly reduce the risk of children suffering from RSV and its complications.

If this drug proves to be effective as originally hoped, this could mark a major milestone in the fight against RSV. [ad_1]

[ad_2]

Resource backlink